Publications

Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Dao TV, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Kurland JF, Balaji K, Abou-Alfa GK. Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer). Future oncology (London, England). 2026. PMID: 42108643

Truong AA, Ho S, Lee RH, Wu X, Kang H, El-Sayed IH, George JR, Heaton CM, Likhterov I, Xu MJ, Ha PK, Algazi AP, Wai KC. Neutrophil-To-Lymphocyte Ratio and Survival in Pembrolizumab-Treated Oropharyngeal Cancer. Head & neck. 2026. PMID: 42108213

Zeng J, Cheng Z, Chen H, Thompson J, Crosby KT, Han H, Ngo W, Xia C, Rosas-Rivera D, Kang MH, Mao Y, Lee G, Diffley JFX, Song Y, Qiu L, Krah NM, Murthy N, Jackson RN, Liu Y, Ashworth A, Doudna JA. Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding. bioRxiv : the preprint server for biology. 2026. PMID: 42146678

Marrero Morales LS, Al-Qaraghli MI, Polen K, Selekwa M, Yeh T, Charles-Obi K, Sang'udi S, Muhunzi D, Liang E, Kivuyo NE, Mushi BP, Maina IW, Mmbaga EJ, Van Loon K, Xu MJ, Gaskill CE, Ibrahim PM. The current landscape and opportunities in gastrostomy care quality improvement in low- and middle-income countries: a scoping review. International health. 2026. PMID: 42104811

Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen A, Estevez M, Cottu P, Thill M, Curigliano G, Rugo HS. Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer. The oncologist. 2026. PMID: 42095602

Lord CJ, Tutt ANJ, Ashworth A. Two decades of PARP inhibitor synthetic lethality in cancer. Nature. 2026. PMID: 42092061

Rajeeve S, Wilkes M, Zahradka N, Tomalin L, Quidwai M, Pan D, Calafat NJ, Cusack M, Aleman A, Serebryakova K, Kappes K, Jackson H, Agte S, Thibaud S, Sanchez L, Richard S, Richter J, Rodriguez C, Cho HJ, Chari A, Jagannath S, Laganà A, Rossi AC, Parekh S. Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma. JCI insight. 2026. PMID: 42084945

Bahlis NJ, Facon T, San-Miguel JF, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje NS, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel KC, Mohty M, Leleu X, Plesner T, Jakubowiak AJ, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK. Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE. Blood advances. 2026. PMID: 42085642

Lacouture ME, Pan A, Maier T, Chen A, Dranitsaris G, Shah NJ, Dang C, Gajria D, Gordon A, Iyengar N, Razavi P, Robson M, Rosen E, Wong S, Harris U, Ketosugbo K, Bravo C, Jain M, Markova A. Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 42084605

Stauffer C, Brantly NW, Beam DW, Bose R, Fiedler G, Fisher LE. 3D printing and prostheses: The current state-of-the-art and future directions. Journal of rehabilitation and assistive technologies engineering. 2026. PMID: 42124558

Orgeta V, Kidd G, Stafford J, Leung P, Marston L, Sidebottom A, Fong L. Characteristics of missing incidents and risk factors for harm for older people with and without dementia in the UK. Age and ageing. 2026. PMID: 42120014

Odintsov I, Tazelaar HD, Lee JC, Damon LE, Devine WP, Jones KD. Novel BRAF fusion in Erdheim-Chester disease with pulmonary manifestations: Importance of RNA-based testing and response to MEK inhibition. Histopathology. 2026. PMID: 42082348

Chow R, Zhang D, Kannout S, Ma A, Zheng C, Blayne A, Dou A, Talwar S, Fazelzad R, Rugo HS, Ruhlmann CH, Iihara H, Affronti ML, Leigh J, Scotté F, Eng L, MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group. Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026. PMID: 42068413

Khozin S, Dreyer NA, Galante D, Liu R, Neumann P, Nussbaum N, O'Shaughnessy J, Rimawi MF, Rugo HS, Tolaney SM, Weiss M, Brufsky A. Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative. Advances in therapy. 2026. PMID: 41843049

Widder J, Bol GM, Simek IM, Ehret F, Abdel-Aty H, Basic S, Chuter D, Daly J, Fairbrother P, Zeqa D, Aboubakar Nana F, Achard V, Corradini S, Correia D, De Ruysscher D, Dingemans AC, Faivre-Finn C, Gillessen S, Guren MG, Hendriks L, Kunz WG, Lecouvet FE, Levy A, Lievens Y, McDonald F, Meattini I, Oppong F, Oprea-Lager D, Palma D, Fredberg Persson G, Remon J, Vandemaele M, van Laarhoven HWM, Verkooijen HM, Visani L, Zilli T, Ost P, Guckenberger M. Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium. The Lancet. Oncology. 2026. PMID: 42061381

Venook AP. How to implement DPYD genotyping into practice. Clinical advances in hematology & oncology : H&O. 2026. PMID: 42096684

Shah NJ, Ababio Y, Eccleston A, Rao D, Kelly SP, Chang J, Lucht S, Paydar C, Van Doren BA, Bland E, John W, Giegerich S, Laney J, Feinberg B, Zarrabi KK. Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma. JAMA network open. 2026. PMID: 42166160

Wang T, Ferreira AC, Hossain NM, Fu D, Hill EG, Jimenez Jimenez AM, Benjamin C, Komanduri KV, Paczesny S. Day-30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation. British journal of haematology. 2026. PMID: 42047487

Li C, Ke F, Zhao H, Mao S, Djibo M, Huang L, He M, Wang M, Wen H, Liu Z, Yu Z, Qi Z, Xavier AR, Nenwani M, Wen B, Peterson N, Sahai V, Nagrath D, Lucas CL, Wymann MP, Gao W, Fong L, Sun D. Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer. Nature cancer. 2026. PMID: 42049931

Chen DD, Zimmer A, Yang DD, Francini E, Patton R, Crowdis J, Chandra P, Bin Riaz I, Hanratty B, Rickles-Young M, Tsuji J, Cibulskis C, Fleharty M, Whelpley B, Reardon B, Park J, Nelson PS, Huang FW, Van Allen EM, Ha G, Choudhury AD. Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer. NPJ precision oncology. 2026. PMID: 42049996